化合物SB-265610
| 中文名称 | 化合物SB-265610 |
|---|---|
| 中文同义词 | 化合物SB-265610;SB 265610,CXCR2拮抗剂 |
| 英文名称 | GSK-CXCR2 |
| 英文同义词 | GSK-CXCR2;N-(2-Bromophenyl)-N'-(7-cyano-1H-benzotriazol-4-yl)urea;SB 265610;1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d] [1,2,3]triazol-7-yl)urea;Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-benzotriazol-7-yl)-;SB265610 >=98% (HPLC);CXCR,nonpeptide,inhibit,Inhibitor,SB-265610,inflammation,recruitment,Delay,SB 265610,healing,neutrophil,SB265610,wound,CXC chemokine receptors |
| CAS号 | 211096-49-0 |
| 分子式 | C14H9BrN6O |
| 分子量 | 357.16 |
| EINECS号 | |
| 相关类别 | 标准品 |
| Mol文件 | 211096-49-0.mol |
| 结构式 |  |
化合物SB-265610 性质
| 沸点 | 527.0±45.0 °C(Predicted) |
|---|---|
| 密度 | 1.77±0.1 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | DMSO：可溶15mg/mL，澄清 |
| 酸度系数(pKa) | 6.13±0.40(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至浅棕色 |
SB-265610 是一种选择性的竞争性非肽变构 CXCR2 拮抗剂。SB-265610 阻断大鼠 CINC-1 诱导的钙动员和中性粒细胞趋化性，IC50 分别为 3.7 nM 和 70 nM。
|
CXCR2
|
In vitro, SB-265610 antagonizes rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization, IC 50 of 3.7 nM, and rat neutrophil chemotaxis in a concentration-dependent manner, IC 50 of 70 nM. SB-265610 reduces the antiapoptotic effect of CINC-1 to the levels of those untreated with CINC-1.
SB-265610 (100 mg/kg/day; oral administration; daily; for 5 days; CXCR2 wild type mice) treatment during the wound repair process markedly delays healing parameters in CXCR2 wild type mice.
| Animal Model: | Wild type mice with nitrogen mustard |
| Dosage: | 100 mg/kg/day |
| Administration: | Oral administration; daily; for 5 days |
| Result: | Markedly impaired the wound healing process. |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/01/25 | HY-50688 | SB-265610 | 1 mg | 600元 | |
| 2024/01/25 | HY-50688 | 化合物SB-265610 SB-265610 | 211096-49-0 | 5 mg | 1500元 |